These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 20552736

  • 1. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabaçam G, Törüner M.
    Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
    [No Abstract] [Full Text] [Related]

  • 2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W, Zhu J, Wang L, Lu Y.
    Eur J Gastroenterol Hepatol; 2013 Aug 23; 25(8):885-91. PubMed ID: 23817447
    [Abstract] [Full Text] [Related]

  • 4. GAIN for loss: adalimumab for infliximab-refractory Crohn disease.
    Mannon P.
    Ann Intern Med; 2007 Jun 19; 146(12):888-90. PubMed ID: 17577009
    [No Abstract] [Full Text] [Related]

  • 5. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I, Faubion WA.
    Inflamm Bowel Dis; 2012 Aug 19; 18(8):1488-92. PubMed ID: 21882301
    [Abstract] [Full Text] [Related]

  • 6. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A, Bonnet D, Thebault S, Alric L.
    Gastroenterol Clin Biol; 2010 Sep 19; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract] [Full Text] [Related]

  • 7. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
    Cravo M, Silva R, Serrano M.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():25-7. PubMed ID: 21175232
    [Abstract] [Full Text] [Related]

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 9. [Adalimumab in Crohn's disease - data from real life].
    López San Román A, Van Domselaar M, Garrido E.
    Rev Esp Enferm Dig; 2008 Nov 14; 100(11):671-5. PubMed ID: 19159169
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S.
    Dtsch Med Wochenschr; 2007 Aug 14; 132(34-35):1770-4. PubMed ID: 17713889
    [Abstract] [Full Text] [Related]

  • 12. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
    Abreu MT.
    Rev Gastroenterol Disord; 2007 Aug 14; 7 Suppl 1():S20-6. PubMed ID: 17392630
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV, Jaganathan S, Bedenbaugh AV, Palmer L, Schwartz DA.
    Curr Med Res Opin; 2014 Sep 14; 30(9):1821-6. PubMed ID: 24884302
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J, Kucharzik T.
    Z Gastroenterol; 2005 Jul 14; 43(7):689-90. PubMed ID: 16001352
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.